Diversified science and technology company Danaher (NYSE: DHR) met Wall Street’s revenue expectations in Q3 2026, with sales up 8.3% year on year to $6.55 billion. Its non-GAAP profit of $2.11 per share was 10% above analysts’ consensus estimates.

Is now the time to buy DHR? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Danaher’s third quarter was characterized by steady execution and a positive market response, as the company’s results aligned with Wall Street’s revenue expectations while surpassing consensus for non-GAAP earnings per share. Management emphasized that the lift in core revenue was driven by improved end market conditions in biotechnology, life sciences, and diagnostics, aided by new product launches and strengthened operational discipline. CEO Julie Sawyer Montgomery noted that customer demand in key verticals such as large pharma and biopharma remained robust, while biotech activity improved and academic markets showed sequential recovery. Montgomery highlighted, “We delivered a nearly 30% adjusted operating profit margin, reflecting both improved end market conditions and the benefit of strong commercial and operational execution.”

Looking ahead, Danaher’s updated guidance for the year reflects expectations of continued momentum from improved commercial execution, a focus on innovation, and ongoing integration of recent acquisitions. Management’s priorities center on accelerating growth through cross-platform collaboration, strategic investment in AI-driven solutions, and greater organizational connectivity. CEO Julie Sawyer Montgomery stated, “Our ambition is to be a leading partner as customers adopt AI, and we believe the full power of our platforms positions us exceptionally well to help accelerate scientific discovery.” The company also flagged ongoing efforts to strengthen its capital allocation approach and drive share gains, while acknowledging that realizing the full potential of these initiatives will require time and sustained operational discipline.

Key insights from management’s remarks

Management attributed revenue growth to stronger demand in bioprocessing, life sciences, and diagnostics, as well as new product introductions and cross-business collaboration.

• Bioprocessing segment momentum: Underlying market demand improved, with strong order growth in upstream consumables and resins supporting high single-digit long-term growth targets. Management credited this to secular drivers such as increased monoclonal antibody launches and the acceleration of biosimilars and new modalities.
• Diagnostics collaboration impact: Coordinated customer engagement across diagnostics businesses led to incremental revenue opportunities and share gains. CEO Julie Sawyer Montgomery described strategic dialogues with key customers as a catalyst for several hundred million dollars of new opportunities.
• AI-enabled solutions adoption: The company launched its first AI-powered autonomous lab at Abcam, integrating robotics and technologies from across its portfolio. Early customer interest was high, and the platform is designed to accelerate reagent discovery eightfold and increase productivity tenfold.
• Recent M&A integration: The acquisition of StatLab by Leica Biosystems strengthened the pathology workflow, while the integration of Masimo progressed ahead of expectations, delivering high single-digit revenue growth and expanding the diagnostics platform’s capabilities.
• End market recovery trends: Life sciences instruments and consumables saw improved demand, particularly from pharma, biopharma, and academic customers. Management also noted easing policy headwinds in China and healthy growth in high-growth markets, contributing to solid segmental performance.

Drivers of future performance

Danaher expects continued growth to be powered by enhanced commercial execution, AI integration, and disciplined capital deployment, while monitoring shifting end market dynamics.

• AI and automation expansion: Management is prioritizing investment in AI-driven laboratory automation and workflow solutions, aiming to support faster scientific discovery and deepen customer partnerships. The company believes its breadth in instruments, consumables, automation, and software makes it well-positioned as AI adoption grows in life sciences and diagnostics.
• Capital allocation and M&A discipline: Ongoing focus on strategically compounding mergers and acquisitions is expected to drive long-term value creation. Management emphasized that recent deals, such as Masimo and StatLab, are intended to strengthen existing platforms rather than shift Danaher’s market orientation.
• End market variability and risks: While management is optimistic about recovery in biotech and improvement in academic and applied markets, they remain cautious regarding the variability of respiratory-related revenue and the timing of large greenfield bioprocessing projects, which are expected to impact results beyond next year.

Catalysts in upcoming quarters

In upcoming quarters, the StockStory team will be closely tracking (1) the pace of adoption and commercialization of Danaher’s AI-powered laboratory solutions, (2) sustained order growth and backlog development in bioprocessing and life sciences, and (3) integration milestones and synergy realization from recent acquisitions like Masimo and StatLab. Execution on commercial excellence and capital deployment will also be key indicators of future performance.

Danaher currently trades at $235.00, up from $224.21 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Our favorite stocks right now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.